跳至主導覽
跳至搜尋
跳過主要內容
國立陽明交通大學研發優勢分析平台 首頁
English
中文
在 國立陽明交通大學研發優勢分析平台 搜尋內容
首頁
人員
單位
研究成果
計畫
獎項
活動
貴重儀器
影響
Potential of circulating immune cells as biomarkers of nivolumab treatment efficacy for advanced hepatocellular carcinoma
Yi Ping Hung
, Yu Yun Shao
, Jan Mou Lee
, Chiun Hsu
, Chih Hung Hsu
,
Muh Hwa Yang
*
, Yee Chao
*
此作品的通信作者
臨床醫學研究所
研究成果
:
Article
›
同行評審
15
引文 斯高帕斯(Scopus)
總覽
指紋
指紋
深入研究「Potential of circulating immune cells as biomarkers of nivolumab treatment efficacy for advanced hepatocellular carcinoma」主題。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Medicine and Dentistry
Advanced Cancer
20%
B Cell
40%
Biological Marker
100%
Clinical Trial
20%
Combination Therapy
100%
Cytotoxic T-Cell
20%
Disease Exacerbation
60%
Diseases
100%
Flow Cytometry
20%
Hepatocellular Carcinoma
100%
Immunocompetent Cell
100%
Immunotherapy
20%
Lymphocyte
20%
Nivolumab
100%
Programmed Death 1 Ligand 1
80%
T Cell
20%
T-Helper Cell
20%
Keyphrases
Advanced Cancer
12%
Advanced Hepatocellular Carcinoma
100%
Anti-programmed death-1 Monoclonal Antibody
12%
CD4 T Cells
12%
CD8+ T Cells
12%
Circulating Immune Cells
100%
Clinical Trials
12%
Complete Response
12%
Days of Treatment
12%
Disease Control
37%
Disease Control Rate
12%
Disease Progression
37%
Flow Cytometry
12%
Hemogram
12%
Immune Cells
12%
Lymphocytes
12%
Monocytes
25%
Nivolumab
100%
Non-associated
25%
Objective Response Rate
12%
Partial Response
12%
Peripheral B Cells
25%
Peripheral Blood
12%
Programmed Death-ligand 1 (PD-L1)
100%
Stable Disease
12%
T Cells
12%
Treatment Efficacy
100%
Treatment Outcome
25%
Pharmacology, Toxicology and Pharmaceutical Science
Advanced Cancer
20%
Biological Marker
100%
CD8 Antigen
20%
Clinical Trial
20%
Combination Therapy
100%
Disease Exacerbation
60%
Diseases
100%
Flow Cytometry
20%
Immunotherapy
20%
Liver Cell Carcinoma
100%
Nivolumab
100%
Programmed Death 1 Ligand 1
80%
Immunology and Microbiology
B Cell
50%
Cytotoxic T-Cell
25%
Immunocompetent Cell
100%
Immunotherapy
25%
Lymphocyte
25%
Nivolumab
100%
Programmed Death 1 Ligand 1
100%
T Cell
25%
T-Helper Cell
25%